Status:
COMPLETED
Effects of Armolipid Plus on Cholesterol Levels and Endothelial Function
Lead Sponsor:
Federico II University
Collaborating Sponsors:
Rottapharm
Conditions:
Hyperlipidemia
Endothelial Dysfunction
Eligibility:
All Genders
18-70 years
Brief Summary
Some nutraceuticals are often advised for their lipid lowering effects. Although many clinical trials have been conducted to assess their efficacy many doubts remain whether they could be considered a...
Eligibility Criteria
Inclusion
- Males and females aged between 18 and 70
- Total cholesterol levels \> 220 mg/dl and LDL-Cholesterol \> 130 mg/dl;
- Patients with concomitant pathology such as diabetes, chronic heart failure, coronary artery disease, arterial hypertension, dysthyroidism, were admitted as long as stable in the previous three months
Exclusion
- Proven intolerance to an Armolipid Plus compound
- Pregnant women, and women planning to conceive
- Patients in therapy with lipid lowering drugs within the previous 6 weeks
- Triglycerides concentration \> 500mg/dl were excluded.
Key Trial Info
Start Date :
July 1 2007
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
April 1 2008
Estimated Enrollment :
50 Patients enrolled
Trial Details
Trial ID
NCT00654459
Start Date
July 1 2007
End Date
April 1 2008
Last Update
April 16 2008
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Department of internal medicine University Federico II
Naples, Italy, 80131